Med Ed 101
AUGUST 27, 2023
I know some folks out there really like crossword puzzles, so I figured why not combine a little fun with a little pharmacology education? I’ve created a free brand/generic crossword puzzle that you should be able to work through below. The main focus of this crossword puzzle is old school medications. The answers to the […] The post Old School Brand/Generic Crossword Puzzle appeared first on Med Ed 101.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
AUGUST 27, 2023
Speed is a critical factor in early-stage development. Solid state studies within an integrated CMC platform can support formulation development, accelerate timelines to phase 1 clinical studies and increase the likelihood of successful clinical trial results.
Pharmaceutical Technology
AUGUST 27, 2023
Patidistrogene bexoparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase II program in Limb-Girdle Muscular Dystrophy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Welltopia Pharmacy
AUGUST 27, 2023
Dive into the fascinating relationship between alcohol and the brain. Learn how alcohol affects brain cells, cognition, and the risk of neurodegenerative disorders. Find out if moderate alcohol consumption can be beneficial for brain health.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
FDA Law Blog: Biosimilars
AUGUST 27, 2023
By Karla L. Palmer — On Friday, August 25, 2023, FDA released a much-anticipated Final Guidance titled, “Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act,” addressing FDA’s implementation of certain electronic interoperability provisions of the Drug Supply Chain Security Act (DSCSA), which were due to become effective on November 27, 2023.
Pharmaceutical Technology
AUGUST 27, 2023
Following public outcry and a government investigation, Allina Health has reneged on their policy barring debtors from out-patient care.
PharmaTech
AUGUST 27, 2023
Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
AUGUST 27, 2023
This chart shows the pharmaceutical companies with the most spray dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most spray dosed drugs… The post Which pharmaceutical companies have the most spray dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Eye on FDA
AUGUST 27, 2023
Having passed the mid-year point, it is always an interesting exercise to take stock of where we stand with respect to the approval of new medicines. Overall, when considering the volume of activity, things would seem to be looking up – at least in terms of the volume of activity. First let’s look at the approval of new molecular entities, and then at the number of Advisory Committee meetings being held, and compare them to the first half of 2022.
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Pharmacy Joe
AUGUST 27, 2023
In this episode, I’ll discuss a clinical prediction model for augmented renal clearance in adult mixed critically ill patients. Episode 847: A Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients Subscribe on iTunes , Android , or Stitcher Augmented or enhanced renal clearance is a phenomenon in some critically ill patients whereby their kidney function becomes supranormal.
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Pharmaceutical Technology
AUGUST 27, 2023
Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction.
Pharmaceutical Technology
AUGUST 27, 2023
Quisovalimab is a monoclonal antibody commercialized by Avalo Therapeutics, with a leading Phase II program in Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Pharmaceutical Technology
AUGUST 27, 2023
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Expert insights. Personalized for you.
97 
Let's personalize your content